From: Assessment of three fasting plasma glucose targets for insulin glargine-based therapy in people with type 2 diabetes mellitus in China: study protocol for a randomized controlled trial
FPG (mmol/L)
Insulin dose
All groups ≤ 3.9 or nocturnal hypoglycemia
- 2 U
Group 1: 3.9 < FPG ≤ 5.6
No change
Group 2: 3.9 < FPG ≤ 6.1
Group 3: 3.9 < FPG ≤ 7.0
Group 1: FPG > 5.6
+2 U
Group 2: FPG > 6.1
Group 3: FPG > 7.0